A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients With Diabetic Kidney Disease Due to Type 1 or Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2017
At a glance
- Drugs LY 2382770 (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 18 Sep 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 25 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2014 Planned End Date changed from 1 Nov 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.